Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorUrsino, Moreno
dc.contributor.authorDimairo, Munyaradzi
dc.contributor.authorSolovyeva, Olga
dc.contributor.authorAshby, Deborah
dc.contributor.authorVillacampa Javierre, Guillermo
dc.contributor.authorRekowski, Jan
dc.date.accessioned2025-03-17T10:54:00Z
dc.date.available2025-03-17T10:54:00Z
dc.date.copyright2024
dc.date.issued2025-01
dc.identifier.citationUrsino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D, et al. SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols. eClinicalMedicine. 2025 Jan;79:102988.
dc.identifier.issn2589-5370
dc.identifier.urihttp://hdl.handle.net/11351/12771
dc.descriptionDose escalation/de-escalation; Dose-finding; Early phase trials
dc.description.abstractTransparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity. To address this gap, the international consensus-driven SPIRIT-DEFINE checklist was developed through a robust methodological framework for guideline development, with the aim to improve completeness and clarity in EPDF trial protocols. The checklist builds on the SPIRIT statement, adding 17 new items and modifying 15 existing ones.The SPIRIT-DEFINE explanation and elaboration (E&E) document provides comprehensive information to enhance understanding and usability of the SPIRIT-DEFINE checklist when writing an EPDF trial protocol. Each new or modified checklist item is accompanied by a detailed description, its rationale with supportive evidence, and examples of good reporting curated from EPDF trial protocols covering a range of therapeutic areas and interventions. We recommend utilising this paper alongside the SPIRIT statement, and any relevant extensions, to enhance the development and review of EPDF trial protocols.By facilitating adoption of the SPIRIT-DEFINE statement for EPDF trials, this E&E document can promote enhancement of methodological rigour, patient safety, transparency, and facilitate the generation of high-quality, reproducible evidence that will strengthen the foundation of early phase research and ultimately improve patient outcomes.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofserieseClinicalMedicine;79
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectMedicaments - Assaigs clínics
dc.subjectPosologia
dc.subject.meshClinical Trials, Phase I as Topic
dc.subject.meshDose-Response Relationship, Drug
dc.titleSPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.eclinm.2024.102988
dc.subject.decsensayos clínicos en fase I como asunto
dc.subject.decsrelación dosis-respuesta de medicamentos
dc.relation.publishversionhttps://doi.org/10.1016/j.eclinm.2024.102988
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ursino M] ReCAP/F CRIN, INSERM, Nancy, France. Unit of Clinical Epidemiology, University Hospital Centre Robert Debré, Université Paris Cité, Paris, France. INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France. HeKA Team, Centre Inria, Paris, France. [Villacampa G] Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK. Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Rekowski J, Solovyeva O] Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK. [Dimairo M] Division of Population Health, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK. [Ashby D] School of Public Health, Imperial College London, St Mary's Hospital, London, UK
dc.identifier.pmid39877554
dc.identifier.wos001399829000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record